JP2009539769A - カペシタビン併用療法 - Google Patents

カペシタビン併用療法 Download PDF

Info

Publication number
JP2009539769A
JP2009539769A JP2009513337A JP2009513337A JP2009539769A JP 2009539769 A JP2009539769 A JP 2009539769A JP 2009513337 A JP2009513337 A JP 2009513337A JP 2009513337 A JP2009513337 A JP 2009513337A JP 2009539769 A JP2009539769 A JP 2009539769A
Authority
JP
Japan
Prior art keywords
cancer
capecitabine
mtor inhibitor
inhibitors
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009513337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539769A5 (enExample
Inventor
ジアンニ、ルカ
ベドロシアン、カミール・エル
Original Assignee
アリアド ジーン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリアド ジーン セラピューティクス インコーポレイテッド filed Critical アリアド ジーン セラピューティクス インコーポレイテッド
Publication of JP2009539769A publication Critical patent/JP2009539769A/ja
Publication of JP2009539769A5 publication Critical patent/JP2009539769A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009513337A 2006-06-02 2007-06-04 カペシタビン併用療法 Pending JP2009539769A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81037106P 2006-06-02 2006-06-02
PCT/US2007/013243 WO2007143212A1 (en) 2006-06-02 2007-06-04 Capecitabine combination therapy

Publications (2)

Publication Number Publication Date
JP2009539769A true JP2009539769A (ja) 2009-11-19
JP2009539769A5 JP2009539769A5 (enExample) 2010-07-15

Family

ID=38801806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009513337A Pending JP2009539769A (ja) 2006-06-02 2007-06-04 カペシタビン併用療法

Country Status (4)

Country Link
US (1) US20090311249A1 (enExample)
EP (1) EP2032168A4 (enExample)
JP (1) JP2009539769A (enExample)
WO (1) WO2007143212A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530446A (ja) * 2016-09-13 2019-10-24 イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV 粘膜付着性微生物

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
EP2549863A4 (en) 2010-03-24 2014-01-01 Univ Ohio COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORTATION
WO2011133636A1 (en) 2010-04-20 2011-10-27 Cedars-Sinai Medical Center COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
CN104271159B (zh) * 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
JP2015508789A (ja) * 2012-03-02 2015-03-23 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 医薬製剤
US9278090B2 (en) * 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders
KR101512223B1 (ko) * 2013-02-22 2015-04-24 가톨릭대학교 산학협력단 펜톡시필린을 포함하는 항암치료 보조제
MX2016004094A (es) * 2013-09-30 2016-10-28 Intas Pharmaceuticals Ltd Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
US11213583B2 (en) 2014-02-05 2022-01-04 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
TW201613563A (en) * 2014-06-12 2016-04-16 Sanofi Synthelabo India Ltd Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof
US10647654B2 (en) 2016-06-24 2020-05-12 Ohio University Glucose transport inhibitors and methods of using same
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン:癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
TWI804499B (zh) * 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
CA3187616A1 (en) 2018-01-18 2019-07-25 Taro Pharmaceutical Industries Ltd. Topical capecitabine for the treatment of hyperproliferative skin conditions
ES2990069B2 (es) * 2023-04-24 2025-06-04 Fundacion Univ San Antonio Ucam Combinacion sinergica para el tratamiento de cancer
CN120789273B (zh) * 2025-07-24 2026-05-05 中山大学附属第一医院 Yap抑制剂联合drd2抑制剂在制备乳腺癌和/或肝癌治疗药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525950A (ja) * 2001-04-06 2004-08-26 ワイス ラパマイシンとゲムシタビンまたはフルオロウラシルなどの、抗腫瘍剤の組み合わせ
JP2005516065A (ja) * 2002-02-01 2005-06-02 アリアド ジーン セラピューティクス インコーポレイテッド リン含有化合物およびその用途
WO2006039414A2 (en) * 2004-09-30 2006-04-13 Ariad Gene Therapeutics, Inc. Treatment method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
EP1648900A4 (en) * 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525950A (ja) * 2001-04-06 2004-08-26 ワイス ラパマイシンとゲムシタビンまたはフルオロウラシルなどの、抗腫瘍剤の組み合わせ
JP2005516065A (ja) * 2002-02-01 2005-06-02 アリアド ジーン セラピューティクス インコーポレイテッド リン含有化合物およびその用途
WO2006039414A2 (en) * 2004-09-30 2006-04-13 Ariad Gene Therapeutics, Inc. Treatment method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012047054; Rizzier,D.A. et al: 'A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hema' BLOOD Vol.106, No.11, 2005 *
JPN6012047055; KINDWALL-KELLER,T. et al: 'Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-smal' CLIN CANCER RES Vol.11, 2005, p.1870-1876 *
JPN7012003661; PACEY,S. et al: 'Results of phase 1 clinical trial investigating a combination of the oral mTOR inhibitor Everolimus' ASCO MEETING , 200409 *
JPN7012003662; PUNT, C.I.J. et al: 'Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combinatio' Annals of Oncology Vol.14, 2003, p.931-937 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530446A (ja) * 2016-09-13 2019-10-24 イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV 粘膜付着性微生物
JP7022743B2 (ja) 2016-09-13 2022-02-18 イントレクソン・アクトバイオテイクス・エヌブイ 粘膜付着性微生物
JP2022084579A (ja) * 2016-09-13 2022-06-07 イントレクソン・アクトバイオテイクス・エヌブイ 粘膜付着性微生物
US11384123B2 (en) 2016-09-13 2022-07-12 Intrexon Actobiotics N.V. Mucoadhesive microorganism
JP7439148B2 (ja) 2016-09-13 2024-02-27 イントレクソン・アクトバイオテイクス・エヌブイ 粘膜付着性微生物
US12252516B2 (en) 2016-09-13 2025-03-18 Intrexon Actobiotics N.V. Mucoadhesive microorganism

Also Published As

Publication number Publication date
EP2032168A1 (en) 2009-03-11
WO2007143212A1 (en) 2007-12-13
EP2032168A4 (en) 2010-12-29
US20090311249A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
US20090311249A1 (en) Capecitabine Combination Therapy
US12527874B2 (en) Bioorthogonal compositions
EP3902547B1 (en) Csf1r inhibitors for use in treating cancer
US20220251165A1 (en) Engineered platelets for targeted delivery of a therapeutic agent
CA3085634C (en) A conjugate of a tubulysin analog with branched linkers
US20220340614A1 (en) Conjugated neuroactive steroid compositions and methods of use
KR20010013419A (ko) 약리학적 활성제와 디티오카르바메이트의 결합체 및 그의용도
CN106793970B (zh) 用于诊断及治疗的纳米载剂及其加工
WO2016050208A1 (zh) 一种多官能化聚乙二醇衍生物修饰的生物相关物质
WO2016050209A1 (zh) 一种异官能化聚乙二醇衍生物、制备方法及其生物相关物质
EP3320902A1 (en) Methods for treating diseases using isoindoline compounds
US9855223B2 (en) Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same
WO2019140324A1 (en) Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation
CN110062633A (zh) 酪氨酸衍生物以及包含所述酪氨酸衍生物的组合物
JP7820798B2 (ja) 赤芽球増殖性プロトポルフィリン症(epp)およびx連鎖プロトポルフィリン症(xlp)のための新規療法
US20210023099A1 (en) Combination therapy with a bet inhibitor and a proteasome inhibitor
JP2020528418A (ja) BET阻害剤及びBcl−2阻害剤を用いた併用療法
WO2021178789A1 (en) Methods of using rebastinib in the treatment of different cancerous disorders
TW516957B (en) Composition for use in reducing nitric oxide levels and inactivating or inhibiting the formation of species that induce the expression of nitric oxide synthase
US20250049936A1 (en) Bioorthogonal compositions
HK40080633A (en) Engineered platelets for targeted delivery of a therapeutic agent
CN117982451A (zh) 治疗癌症及/或癌症转移的方法
WO2024159105A1 (en) Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody
CN119233821A (zh) Pi3k抑制剂与pd-1抑制剂的组合疗法
HK40061268B (en) Csf1r inhibitors for use in treating cancer

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20090827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130226